Novartis in Society Integrated Report 2022

Our medicines

Our medicines treat major diseases, from cancer and heart disease to rare genetic disorders, and are distributed in approximately 140 countries around the world.

We focus on five core therapeutic areas where there are high unmet patient needs:

  • Cardiovascular
  • Immunology
  • Neuroscience
  • Solid Tumors
  • Hematology

In addition, we have research and in-market programs in Ophthalmology and Respiratory.

Through Sandoz, we also offer around 1 000 generics and biosimilars in areas ranging from cardiovascular and respiratory illnesses to conditions affecting the central nervous system.

Top 10 innovative medicines by sales

Brand / 2022 net sales (USD, millions)

  • Cosentyx An injectable treatment for several systemic inflammatory conditions

    4 788

  • Entresto An oral medicine for heart failure and hypertension

    4 644

  • Promacta/Revolade An oral treatment for certain blood disorders

    2 088

  • Gilenya An oral treatment for relapsing forms of multiple sclerosis

    2 013

  • Tasigna An oral treatment for a type of chronic myeloid leukemia

    1 923

  • Lucentis An injectable medicine for certain conditions of the retina

    1 874

  • Tafinlar + Mekinist An oral combination therapy for certain types of skin, thyroid and lung cancers

    1 770

  • Jakavi An oral therapy for certain rare blood disorders

    1 561

  • Zolgensma A one-time intravenous gene therapy for spinal muscular atrophy in babies and young children

    1 370

  • Xolair An injectable therapy for certain respiratory and immunological conditions, including severe allergic asthma

    1 365

A Novartis researcher (Photo)

Topic filter